Mark Coffin, Ph.D., has more than 30 years of experience in pharmaceutical development and manufacturing.  He retired from GlaxoSmithKline in 2015 as a Senior Director and then worked in two start-up biotech companies from 2015 to 2022, getting one product approved by the FDA and launched in the US.  He is currently serving as a consultant for clients spanning from pre-Phase 1 development to post-approval commercialisation support.  Mark has deep technical expertise in the development of solid oral dosage forms as well as novel dosage forms, including gastro-retentive devices.